BioSciences announced the first patient has been dosed in the Phase 2 ASCEND study of PCRX-201 for the treatment of ...

In general terms, interleukin 1 seems to contribute directly ... the function of P2X7 receptors, caspase 1 activity, receptor binding and intracellular signalling pathways. The most advanced ...

Summary: Tocilizumab is a novel monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6) to its receptor (IL-6R). Inhibiting the entire receptor complex prevents IL-6 ...